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Abstract 
 
Taweenan, W. 2004. Vaccination against toxoplasmosis. Immune responses in mice 
immunised with a recombinant Toxoplasma gondii antigen. Master of Science thesis. 
Report no. 41, ISSN 1403-2201. 
 
The intracellular protozoan parasite Toxoplasma gondii can infect a wide range of animal 
species, and is one of the main causes of infectious abortion and perinatal mortality in 
sheep. In humans, the parasite can cause abortion and congenital infection, and fatal disease 
in immunosuppressed patients. In sheep, toxoplasmosis can be controlled by vaccination 
with a live, attenuated vaccine. However, since such a vaccine has practical disadvantages 
and is not acceptable for use in humans, various strategies to develop an effective subunit 
vaccine have been explored. The major surface antigen of T. gondii, named SAG1, is 
considered as a promising vaccine candidate. Equally as important as identification of 
protective antigens is the choice of adjuvant. The immunostimulating complex (iscom) is an 
adjuvant formulation that induces both humoral and cellular immune responses that are 
predominantly of type 1, and therefore is likely to be effective against intracellular 
parasites.  
 
The aim of the present study was to produce iscoms containing recombinant SAG1 
(rSAG1) and to investigate their immunogenicity and protective capacity against T. gondii 
using a mouse model. 
 
   SAG1 expressed in E. coli as a recombinant protein with a hexahistidyl (His6) tag was 
coupled to preformed iscom matrix (i.e. iscom particles without any antigen) using the 
affinity of the His6 tag to divalent anions. The matrix contained a chelating lipid and had 
been loaded with Ni2+ ions. Analytical density gradient centrifugation revealed that a 
substantial proportion of the SAG1 had bound to the matrix. To investigate the 
immunogenicity of the rSAG1 iscoms, mice were immunised twice and the cellular immune 
response examined by in vitro stimulation of spleen cells. Cells from three of four 
immunised mice proliferated significantly when exposed to rSAG1, whereas cells from 
only one of five mice were stimulated with T. gondii lysate. ELISA analysis revealed high 
antibody titres against rSAG1 but only low levels against T. gondii antigens. In two 
subsequent challenge experiments, three groups of mice were inoculated three times with 
either rSAG1 iscoms, iscom matrix, or PBS. The third immunisation resulted in 
substantially higher antibody titres against T. gondii antigen. After inoculation with the 
virulent RH strain all mice died without any significant differences in survival time 
between groups (p = 0.179). However, when the mice were inoculated orally with tissue 
cysts of the Tg-SweF1 strain, significantly lower numbers of brain cysts were found in mice 
immunised with rSAG1 iscoms than in mice injected with PBS (p < 0.05).  
 
   In conclusion, although immunisation with rSAG1 iscoms did not protect mice from the 
lethal challenge infection, partial protection was induced as demonstrated by the reduction 
of brain cyst load after inoculation with an avirulent strain. 
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General background 
 
Introduction 
Toxoplasma gondii is an obligate intracellular protozoan parasite with an 
extremely wide geographic and host range.  It belongs to the family Sarcocystidae, 
in the phylum Apicomplexa (Long, 1990). This phylum also includes other 
important parasites such as Plasmodium (the cause of malaria), Eimeria (the cause 
of chicken coccidiosis) and Neospora (the cause of neosporosis in cattle). 
Morphologically, T. gondii is similar to Neospora caninum. Before N. caninum 
was identified as a separate species, it was misdiagnosed as T. gondii (Dubey et 
al., 1988). Today, there is obvious evidence, such as ultrastructural (Lindsay et al., 
1993; Speer et al., 1999), antigenic (Howe and Sibley, 1999) and genetic 
differences (Brindley et al., 1993), indicating that they are distinct.  T. gondii was 
first described in 1908 by Nicolle and Manceaux. The name Toxoplasma is 
derived from its crescent shape (toxon = arc, plasma = form, Greek). Cats and 
other felid species are definitive hosts (Miller et al., 1972), with humans and a 
wide range of warm-blooded animals acting as intermediate hosts. Toxoplasmosis 
is an important disease causing abortion in sheep and other animal species. It is 
also a cause of abortion and congenital abnormalities in humans. Moreover, in 
immunosuppressed individuals it can develop into a fatal disease. 
 
Life cycle 
The life cycle of T. gondii has an asexual and a sexual part. The asexual cycle 
involves two parasite stages, tachyzoite and bradyzoite. The tachyzoite is crescent-
shaped, 5 µm by 2 µm in size (Smith, 1995). It can actively enter the host cell, and 
thereafter becomes ovoid and surrounded by a parasitophorous vacuole. The 
tachyzoite multiplies rapidly by endodyogeny (two daughter cells form within the 
mother cell) until the host cell ruptures. The released free tachyzoites penetrate 
new host cells, and the replication proceeds until the host dies or develops 
immunity to the parasite. In the latter case, the intracellular tachyzoites 
differentiate into bradyzoites, whereas extracellular parasites are eliminated. The 
bradyzoites are morphologically similar to tachyzoites, and multiply slowly within 
tissue cysts. These tissue cysts are found predominantly in the central nervous 
system and skeletal muscles. A small tissue cyst contains few bradyzoites while a 
large one can contain thousands. The tissue cysts represent the quiescent stage and 
can remain viable for the lifetime of the host. If the cysts rupture, the bradyzoites 
are released and become active tachyzoites that invade new host cells and then 
start to proliferate again. The asexual cycle can occur in both the definitive host 
and the intermediate host (Black and Boothroyd, 2000; Martin and Aitken, 2000). 
 
The sexual part, which takes place only in the definitive host, begins when a non-
immune cat ingests tissue cysts containing bradyzoites. The tissue cysts are 
digested by proteolytic enzymes in the small intestine, and bradyzoites are 
released. The bradyzoites penetrate into the epithelial cells and replicate asexually. 
After the cells break, some parasites spread via the lymphatic system and 
  10
bloodstream to other organs. Simultaneously with the multiplication and 
dissemination to extra-intestinal tissues, the sexual cycle, gametogony, begins in 
the epithelial cells of the small intestine. Found from day 3 to 15 after ingestion of 
tissue cysts, the gametocytes occur throughout the entire length of small intestine, 
but mainly in the ileum. The male microgamete enters the female macrogamete, 
which becomes a zygote and then develops into spherical-shaped oocyst, filled 
with a sporont. The oocyst is expelled into the intestinal lumen and excreted into 
the cat’s faeces, but is not infective until it has sporulated.  Sporulation takes 1 to 
5 days depending on environmental factors such as aeration and temperature. The 
sporulated oocyst is subspherical to ellipsoidal, 11 µm by 13 µm in size, and 
contains 2 ellipsoidal sporocysts, each filled with 4 crescent-shaped sporozoites, 2 
µm by 6 to 8 µm.  The oocysts can remain infective for at least 410 days if kept at 
4 °C or in the environment if not exposed to direct sunlight. Since cats usually 
bury their faeces, the infective oocysts can be transmitted to other animals for a 
year (Yilmaz and Hopkins, 1972). Widespread natural infection is not surprising 
since a cat may shed millions of oocysts after ingestion of an infected mouse. 
Oocysts can also be transported by invertebrates such as flies, cockroaches and 
earthworms, and by rain and snow (Dubey and Towle, 1986). 
 
   
 
Fig. 1. Toxoplasma gondii oocysts (A): sporulated (large arrow) and unsporulated oocyst 
(small arrow). Tissue cyst in homogenised brain tissue (B). (Photo: x and S. Pinitkiatisakul) 
 
 
In cats, the prepatent period (the time from infection to the shedding of oocysts) 
varies depending on the stage of T. gondii ingested.  After ingesting tissue cysts, it 
is 3 to 10 days, 19 days or longer after ingesting tachyzoites, and 20 days or longer 
after ingesting oocysts (Dubey and Beattie, 1988).  After a primary infection cats 
become immune, and do not usually shed oocysts again if reinfected. This 
immunity can remain for up to 6 years. However, some cats will shed oocysts 
again if reinfected, but then only in smaller amounts than after the primary 
infection (Dubey, 1995). 
 
Vertical transmission can occur if non-immune animals become infected during 
the gestation period. This can lead to abortion or congenital infection. However, 
the susceptibility varies in different animal species.  For instance, abortion due to 
T. gondii is common in sheep while it rarely occurs in cattle (Dubey and Beattie, 
1988). 
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Fig. 2. Life cycle of Toxoplasma gondii. 
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Toxoplasmosis in sheep 
There are several reports describing abortion in sheep caused by T. gondii (Dubey 
and Schmitz, 1981; Dubey and Welcome, 1988). Susceptible sheep can be 
infected by ingestion of food or water contaminated with sporulated oocysts. After 
lysis of the oocyst wall in the small intestine, the released sporozoites pierce the 
epithelial cells, become tachyzoites and start to multiply. Tachyzoites can be 
detected in the mesenteric lymph nodes 4 days after infection. Asexual 
multiplication continues, and some tachyzoites are distributed to various organs. In 
a pregnant ewe, the parasites can invade the gravid uterus and cause focal damage 
in the caruncular septa at day 10 after infection, and the degenerative changes can 
spread to the crypt wall and trophoblast at day 15 day (Buxton and Finlayson, 
1986). The results of infection during the early period of gestation are fetal 
absorption or abortion, while later infection may result in stillbirth or normal but 
infected and immune offspring (Martin and Aitken, 2000).  
 
In abortion cases, multifocal necrosis and calcification might be seen in the 
placenta. The placental cotyledons can be bright to dark red (Beverley et al., 
1971). Parasites might be detected in the placenta and in the fetal heart, brain, lung 
or liver (Dubey et al., 1986b; Dubey et al., 1981; Owen et al., 1998). 
Microscopically, necroses might be found in the white matter of the fetal 
cerebellum and cerebrum. Focal lymphoid-cell proliferations and micronecroses 
might be presented in fetal kidneys, adrenals, lymph nodes or brain.  
 
In order to diagnose toxoplasmosis in sheep, several methods can be applied. 
The clinical picture and history of incidence can suggest a preliminary diagnosis. 
Examination of aborted fetuses and maternal placentas can reveal lesions 
suggestive of toxoplasmosis. For confirmation, more specific methods are 
required, such as immunological methods, polymerase chain reaction (PCR) or 
isolation of the parasite by mouse inoculation (Masala et al., 2003; Owen et al., 
1998; Wastling et al., 1993). Immunohistochemical methods have been developed 
to detect T. gondii in fetuses and fetal membranes (Uggla et al., 1987). Antibodies 
against T. gondii from neonatal or maternal serum can be detected by serological 
methods such as enzyme-linked immunosorbent assay (ELISA) (Björkman and 
Lundén, 1998), haemagglutination inhibition test (HI) (Chang et al., 1985) or 
indirect fluorescent antibody test (IFAT) (Masala et al., 2003; Uggla and Nilsson, 
1987). These serological techniques are also useful for the epidemiological study 
of T. gondii infection. 
 
Toxoplasmosis in other animals 
While toxoplasmosis commonly affects sheep and can cause considerable 
economic losses, there are relatively few reports of clinical disease in other farm 
animals. In pigs, T. gondii infection has been studied because undercooked pork 
containing tissue cyst is considered as an important source of human 
toxoplasmosis.  There are many repots about the prevalence of T. gondii infection 
in pigs in different countries. For example, Lundén et al. (2002) reported that in 
Sweden the seroprevalence was 3.3% in fattening pigs and 17.3% in adult swine. 
Gamble el al. (1999) investigated the prevalence of T. gondii infection in domestic 
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pigs in the New England states of the U.S.A. Using a modified direct agglutination 
test, they found that 47.4% of all tested sows were seropositive and 77 of 85 herds 
tested had at least one positive pig, which gave a herd prevalence of 90.6%. It has 
been demonstrated that experimental infection during pregnancy can cause 
transplacental transmission and abortion (Dubey and Urban, 1990; Jungersen et 
al., 2001). 
 
Natural outbreaks of toxoplasmosis can occur in goats. The clinical signs are 
mainly abortions and stillbirths. Isolation of viable parasites from placenta and 
aborted kids has been repoted (Dubey, 1981a). Pathological lesions characteristic 
of T. gondii infection are multifocal necrosis in the placenta, and focal gliosis and 
calcification in the brain of aborted fetuses (Dubey et al., 1986a). At the time of 
abortion, the antibody titre of the doe can reach up to 1:2,048 using the indirect 
haemagglutination (IHA) test (Dubey et al., 1981).  Abortion induced by 
experimental infection has also been investigated. In transplacentally infected 
kids, T. gondii might be isolated from the heart, brain, skeletal muscle, lungs or 
liver (Dubey, 1981b).  
 
Cattle appear to be more resistant to toxoplasmosis than are sheep. There are 
only a few reports of abortion due to toxoplasmosis in cattle. For instance, there is 
a recent report of isolation of viable T. gondii from a naturally aborted calf 
(Canada et al., 2002). Nevertheless, it has been shown that experimental infection 
can induce transplacental transmission and abortion (Stalheim et al., 1980).  
 
Toxoplasmosis in laboratory animals 
Animal models for toxoplasmosis have been used for numerous reasons. For 
instance, they are used to study the pathology of cerebral, ocular and congenital 
toxoplasmosis as well as for immunological and therapeutic studies.  Experimental 
animals can be divided into two groups according to their resistance to T. gondii, 
with rats and Old World monkeys in the resistant group and mice, hamsters, 
guinea pigs and New World monkeys in the sensitive group. Different animal 
species are used for different experimental purposes since they display a variety of 
pathological lesions after infection. Mice are very often used because of their 
small size and the availability of immunological reagents. Numerous strains of 
mice have been used, such as BALB/c, NMRI, Swiss-Webster, C3H, or C57BL/6j. 
However, although the mouse is a natural host of T. gondii, other species might be 
more suitable for study of certain aspects of toxoplasmosis (Darcy and Zenner, 
1993).  
 
Antigens of T. gondii 
Much of the research on the antigenic structure of T. gondii has focused on surface 
membrane antigens and antigens released from secretory organelles. The 
tachyzoite of the RH strain is often used to study the characteristics of T. gondii 
antigens.  
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There are several surface antigens, and they were first named by their molecular 
weights, e.g. P22 for its apparent mass of 22 kDa. Currently, a naming system 
based on three letters related to the cellular location of the protein is used. For 
example, SAG1 (Surface AntiGen 1) is used for the major tachyzoite surface 
protein previously named P30. Likewise, other surface antigens are named SAG2 
(P22) or SAG3 (P43). Other minor antigens found on the surface are SRS1 
(SAG1-related sequence 1) or SRS2 (SAG1-related sequence 2) (Boothroyd et al., 
1998).  
 
As a member of the Phylum Apicomplexa, T. gondii contains an apical complex 
consisting of organelles at the anterior part. These organelles include polar rings, 
conoid, rhoptries, micronemes and dense granules. Antigens released from the 
dense granules are named GRA1 (P24), GRA2 (P28), GRA4 (P41) and GRA7 
(P29), and ROP1 (P66); and ROP2 (P54) are secreted from rhoptries. 
 
The major T. gondii tachyzoite surface antigen, SAG1, has been widely studied. 
It is one of the immunodominant antigens, and it has been shown to play a role as 
a ligand binding to the host cell during invasion (Grimwood and Smith, 1992; 
Mineo and Kasper, 1994).  Its potential as a diagnostic reagent has also been 
evaluated. SAG1 is a highly conformational antigen, and its recognition by 
antibodies is dependent upon the correct folding. Antiserum to native antigen does 
not, or does only poorly, recognise the reduced or incorrectly folded form of 
SAG1. For example, this has caused problems when bacterial expression systems 
have been used to produce recombinant SAG1 (rSAG1), while eukaryotic systems 
generally have worked well. The appropriate synthesis of rSAG1, expressed in 
CHO cells, was demonstrated as proper folding (Kim et al., 1994). However, an 
rSAG1 fusion protein with six histidyl residues at the N-terminal was successfully 
expressed in E. coli. This recombinant protein is recognised by T. gondii-specific 
human IgG and IgM (Harning et al., 1996). 
 
Immunity to T. gondii 
When infected with T. gondii, immunocompetent animals generally develop 
immune responses that effectively control the infection and protect against 
reinfection. Since T. gondii is an intracellular parasite, the infection is mainly 
controlled by cellular immune mechanisms. However, antibodies also play a role 
in regulation of the infection. 
 
The cytokine gamma interferon (IFN-γ) has been identified as a major mediator 
of resistance against T. gondii (Suzuki et al., 1988). IFN-γ is predominantly 
released by T cells and natural killer (NK) cells. It activates macrophages to 
destroy intracellular parasites and cytotoxic T cells to destroy T. gondii infected 
cells. It has been suggested that in case of chronic toxoplasmosis, IFN-γ protects 
against recurrent disease by preventing cyst rupture. This was demonstrated in 
mice chronically infected with the avirulent ME49 strain. When the mice were 
given a monoclonal antibody (mAb) against IFN-γ, encephalitis was induced and 
tachyzoites and T. gondii antigen were observed around the periphery of the tissue 
cysts, indicating cyst disruption (Suzuki et al., 1989). Giving anti-IFN-γ mAb to 
mice also led to increased mortality after T. gondii infection (Suzuki and 
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Remington, 1990). IFN-γ can protect against acute toxoplasmosis without 
collaboration of lymphokines derived from T cells. This has been shown in 
athymic mice, which lack T cells. When recombinant IFN-γ (rIFN-γ) was given 
every other day after infection, the mice survived, but after cessation of giving 
rIFN-γ the mice died (Suzuki et al., 1991). 
 
The crucial role of T cells against T. gondii infection has been demonstrated in a 
number of studies. Suzuki and Remington (1988) showed that passive transfer of 
T cells from immune mice to naïve recipients conferred protection. Among T cell 
subsets, the cytotoxic CD8+ T lymphocytes (CTL) were found to be the most 
important against T. gondii infection (Suzuki and Remington, 1988). Adoptive 
transfer of CD8+ cells increased survival time and reduced brain cysts in 
challenged mice. It was also shown that these cytotoxic CD8+ T cells produced 
IFN-γ and interleukin-2 (IL-2) (Khan et al., 1991; Parker et al., 1991). The killing 
effect of CD8+ cells has been demonstrated in vitro by lysis of T. gondii infected 
mastocytoma cells (Subauste et al., 1991) and macrophages (Hakim et al., 1991).  
 
Besides the cytotoxic T cells, the helper T cells are also important against 
toxoplasmosis. At least in mice, they are generally subdivided into T helper 1 
(Th1) and T helper 2 (Th2) subpopulations according to the cytokines they 
produce. The Th1 cells secrete IFN-γ, IL-2 and beta tumor necrosis factor (TNF-β 
whereas the Th2 cells produce IL-4, IL-5, IL-10 and IL-13 (Mosmann et al., 1986; 
Tizard, 2000). Immunity against toxoplasmosis is associated with a Th1 type of 
response (Gazzinelli et al., 1991). 
 
The synergistic effects and relative importance of CD4+ and CD8+ T cells have 
been demonstrated by depletion of one or both subsets. Depletion of CD4+ T cells 
in naïve mice led to increased susceptibility and increased cyst burden and 
mortality after inoculation with an avirulent strain of T. gondii (Araujo, 1991). In 
chronically infected mice depletion of either CD4+ or CD8+ T cells did not cause 
any reactivation, while depletion of both subsets resulted in activation of the 
infection (Gazzinelli et al., 1992). Protective immunity can be induced by 
vaccination with an avirulent non-persistent strain of T. gondii. In vaccinated 
mice, the administration of both anti-CD4+ and anti-CD8+ antibody or anti-IFN-γ 
completely abrogates the resistance to the infection, whereas giving anti-CD4+ 
does not affect immunity. Giving anti-CD8+ antibody partially reduces resistance 
to the infection (Gazzinelli et al., 1991). Interestingly, an increase of NK cells, 
another important source of IFN-γ, was observed during T. gondii infection 
(Haque et al., 1999).  
 
Although cell-mediated immune responses play the essential role in immunity 
against toxoplasmosis, antibodies also contribute. For example, specific antibodies 
against SAG1 have been found to inhibit invasion of human fibroblast cells by 
tachyzoites (Mineo et al., 1993). This was confirmed in another study showing 
that both monoclonal and polyclonal antibodies against rSAG1 partially inhibited 
the adhesion and/or invasion of host cells by T. gondii tachyzoites (Petersen et al., 
1998). In natural infection, antibodies might neutralise extracellular tachyzoites 
through opsonisation or complement activation. 
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Development of vaccines against toxoplasmosis 
Numerous strategies for development of vaccines against toxoplasmosis have been 
investigated. Inoculation with live parasites effectively induces protection against 
reinfection, and one strategy is to use avirulent non-persistent strains for 
vaccination. One such strain is the temperature-sensitive mutant strain (ts-4), 
which has been shown to be non-pathogenic to mice and not cause any persistent 
infection (Waldeland et al., 1983). It was also found that inoculated mice were 
well protected against lethal challenge infection. In contrast, mice inoculated with 
a lysate of killed T. gondii tachyzoites were not protected, neither when the lysate 
was given alone nor with an adjuvant such as Freund’s incomplete or complete 
adjuvant (Waldeland and Frenkel, 1983). At present, there is a live commercial 
vaccine for sheep (Toxovax) containing the non-persistent S48 strain. The vaccine 
is used for prevention of ovine abortion due to toxoplasmosis (Buxton and Innes, 
1995). 
 
Generally, although live vaccines can induce protective immunity, they are not 
acceptable for use in humans. Subsequently, different T. gondii antigens have been 
studied using different adjuvants and antigen delivery systems. To evaluate the 
effect of experimental vaccines, increased survival, decreased tissue-cyst burden, 
prevention of congenital transmission or protection against abortion might be 
considered. Much work has been focused on SAG1, the major tachyzoite surface 
antigen, since it has been identified as one of the most promising vaccine 
candidates. For instance, when used with liposomes, which act as a stimulator of 
Th1 responses (Powers et al., 1995), significant protection was induced in mice 
(Bülow and Boothroyd, 1991).  
 
Presently, recombinant vaccines have been investigated, and many T. gondii 
antigens have been produced and their protective effect evaluated. For example, 
immunisation of mice with recombinant SAG1 (rSAG1), expressed in E. coli and 
with alum as adjuvant, resulted in significant protection against challenge with RH 
strain tachyzoites (Petersen et al., 1998). When the protein was given together 
with interleukin-12 (IL-12), decreased brain cyst load and a Th1 type of immunity 
were recorded (Letscher-Bru et al., 1998). Similarly, vaccination of mice with 
rSAG1, expressed in yeast Pichia pastoris with SBAS1c adjuvant, gave a 
protective effect and directed immunity towards a Th1 response (Biemans et al., 
1998). In guinea pigs, P. pastoris-expressed rSAG1 induced protective immunity 
and prevented congenital toxoplasmosis (Haumont et al., 2000).  
 
Also, other T. gondii antigens have been studied and found capable of 
stimulating protective immunity, for example SAG2, SRS1 (Mishima et al., 2001), 
GRA2, and GRA5 (Zenner et al., 1999). 
 
DNA vaccines, i.e. injection of a naked DNA plasmid into the host, whose cells 
then express the encoded protein, have also been studied. Immunisation of mice 
with a plasmid encoding the SAG1 gene (p1tPASAG1) yielded almost complete 
protection against the virulent RH strain (Nielsen et al., 1999). Reduction of brain 
cysts was also obtained in mice and rats immunised with a DNA plasmid encoding 
SAG1 (Angus et al., 2000). Recently, immunisation of mice with a DNA cocktail 
containing plasmids encoding the SAG1 and ROP2 genes resulted in a Th1-type 
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response, and specific T-cell proliferation and IFN-γ production. Also, significant 
long-lasting protection was observed after challenge infection with the virulent 
RH strain (Fachado et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  18
Introduction to the research report 
 
The present research report describes a vaccination experiment with rSAG1 
administered together with immunostimulating complexes (iscoms). The iscom is 
an adjuvant formulation that was first described by Morein et al. (1984). The 
concept is to present surface membrane proteins in multimeric form by 
incorporating them into a matrix consisting of Quil A, phospholipid and 
cholesterol. Quil A is a semipurified product of the extracted crude saponin from 
the bark of the tree Quillaja saponaria Molina. The glycoside Quil A forms 
micelles with phospholipid and cholesterol, which appear as a matrix to which 
amphipathic proteins can be attached by hydrophobic interaction. The iscoms are 
cage-like structures 35-40 nm in diameter (Morein et al., 1984). 
 
The iscoms are highly immunogenic, and effectively induce both humoral and 
cellular immune responses. Some characteristics of the responses induced by 
iscoms are: increased major histocompatibility complex (MHC) class II expression 
on antigen-presenting cells; activation of T helper cells, particularly Th1; and CTL 
activation (Lundén et al., 1996).  
 
Iscoms containing a number of T. gondii antigens extracted from tachyzoites 
have been evaluated in a number of studies of mice and sheep. Immunisation of 
mice with these iscoms resulted in the induction of humoral and cellular immune 
responses, and partial protection against lethal infection. Characterisation of the 
incorporated antigens showed that two major components were the surface 
antigens SAG1 and SAG2 (Lundén et al., 1993; Uggla et al., 1988). In another 
study, mice immunised with iscoms prepared from tachyzoites of two different 
strains of T. gondii developed antibodies to T. gondii and specific cell 
proliferation, but were not protected against the challenge infection (Øvernes et 
al., 1991). 
 
In sheep, this experimental iscom vaccine generated antigen-specific humoral 
and cellular immune responses (Lundén, 1995). However, in a vaccination trial no 
significant protection against abortion could be demonstrated (Buxton et al., 
1989).  
 
Another application of the iscom concept is the preparation of antigens for use 
in immunoassay. For the diagnosis of T. gondii infection, surface antigens are 
generally specific while intracellular proteins can cause unspecific cross reactions. 
Since the iscom production procedure selects amphipathic proteins, such as 
surface proteins, T. gondii iscoms are excellent as an antigen in ELISAs 
(Björkman and Lundén, 1998).  
 
As mentioned above, SAG1 has been highlighted due to its strong 
immunogenicity and capacity to stimulate protective immunity and iscoms appear 
as a suitable antigen-presenting system. Consequently, in the present research 
iscoms containing rSAG1 were produced and evaluated in mice. The 
characteristics of the iscoms were analysed as regards morphology and protein 
content. Antibody- and cell-mediated immunity were evaluated using T. gondii 
iscoms or a tachyzoite lysate as antigen. In addition, challenge infections with one 
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virulent and one avirulent T. gondii strain were performed to test the protective 
effect of the iscom vaccine. 
 
Aims of the study 
 
The aim of present study was to investigate the immune responses of mice after 
immunisation with rSAG1 coupled to iscoms, and to test the protective effect 
against infection with a virulent strain and a cyst-forming (avirulent) strain of T. 
gondii. 
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Abstract 
The present study describes immune responses in mice immunised with the major 
surface antigen (SAG1) of Toxoplasma gondii, expressed in E. coli. The 
recombinant protein (rSAG1) was coupled to immunostimulating complexes 
(iscoms), and the protective effect against infection with two different T. gondii 
strains was evaluated. After two immunisations, significant SAG1-specific 
proliferative responses were detected in three of four BALB/c mice whereas only 
one of five mice were stimulated in vitro with T. gondii lysate. The vaccinated 
mice produced high levels of antibodies against rSAG1 but only low levels against 
T. gondii antigens. Mice immunised three times and then challenged with 104 
tachyzoites of the virulent RH strain did not survive longer than the non-
immunised control (p = 0.179), although high antibody titres against T. gondii 
antigens were detected. However, NMRI mice immunised three times with rSAG1 
iscoms and inoculated with 30 cysts of the avirulent Tg-SweF1 strain had 
significantly lower brain cyst burdens than mice given PBS (p < 0.05). To 
conclude, it was found that although immunisation with rSAG1 iscoms did not 
protect mice from the lethal challenge infection, it induced partial protection 
sufficient to reduce the number of brain cysts after infection with an avirulent 
strain.  
 
Key words: Toxoplasma gondii, subunit vaccine, recombinant immunogen, SAG1, 
iscom, immune response 
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1. Introduction 
Belonging to the Phylum Apicomplexa, Toxoplasma gondii is an intracellular 
protozoan parasite with an extremely wide geographic and host range. Its life 
cycle includes cats and other felids as definitive hosts and humans and warm-
blooded animals as intermediate hosts. Humans can become infected by ingestion 
of infective oocysts from cat faeces or undercooked meat containing tissue cysts. 
In pregnant women who encounter a primary infection, T. gondii can cause 
abortion and congenital abnormalities. Moreover, fatal infection can develop in 
immunocompromised individuals (Bergin et al., 1992). The infection is also of 
veterinary importance, and can cause economic losses when non-immune pregnant 
sheep become infected and result in absorption of foetus, abortion or stillbirth. 
Sheep become infected by ingestion of infective oocysts in contaminated food or 
water (Dubey and Beattie, 1988). In pregnant sheep, only primary infection can 
cause damage, whereas reinfection does not affect the foetus (Uggla and Buxton, 
1990).  
 
To control and prevent toxoplasmosis, different strategies to develop vaccines 
have been applied. In the beginning, live attenuated vaccines were evaluated and 
found to be effective whereas killed vaccines were found to be ineffective 
(Waldeland and Frenkel, 1983). For sheep, a commercial vaccine is available for 
control of Toxoplasma abortion (Toxovax). It contains live tachyzoites of the 
'incomplete' S48 strain of T. gondii (Buxton and Innes, 1995). However, although 
effective in sheep a live vaccine is not acceptable for use in humans since it might 
revert to being harmful. 
 
During the last decade, it has been shown that experimental, killed vaccines can 
induce protective immunity. One of these consists of a number of tachyzoite 
surface proteins (Lundén et al., 1993) incorporated into immunostimulating 
complexes (iscoms) (Morein et al., 1984). It has been found to induce partial 
protection in mice against lethal challenge infection (Lundén et al., 1993; Uggla et 
al., 1988). In sheep, this experimental vaccine evoked specific humoral and 
cellular immune responses (Lundén, 1995). However, the immunity was not 
sufficient to give any significant protection against abortion (Buxton et al., 1989). 
Taken together these results indicate that vaccines using iscoms as adjuvant can 
stimulate strong immune response, and encourage further development to improve 
the protective effect.  
 
The major surface antigen SAG1 (previously named P30) of T. gondii 
tachyzoites is considered to be a main candidate antigen for vaccine development. 
The immunising effects of native or recombinant SAG1 (rSAG1) together with 
different adjuvants have been investigated by several research groups. For 
example, immunisation with bacterially expressed rSAG1 with alum as adjuvant 
was found to induce partial protection against lethal challenge infection in mice 
(Petersen et al., 1998). 
 
The aim of the present study was to investigate the immune responses in mice 
after immunisation with rSAG1 incorporated into iscoms, and to test the protective 
effect against infection with a virulent strain and a cyst-forming (avirulent) strain 
of T. gondii. 
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2. Materials and methods 
2.1 Production of rSAG1 
The rSAG1 was expressed in E. coli as a fusion protein with a hexahistidyl (His6) 
tag, and purified on a Ni2+-chelate column (Harning et al., 1996). After elution of 
the protein, the buffer was changed to one containing 20 mM Tris (pH 7.9), 1000 
mM KCl and 20% glycerol by passage through a PD-10 column (Amersham 
Pharmacia Biotech, Uppsala, Sweden).  
 
2.2 Preparation of rSAG1 iscoms 
The iscoms were prepared by the method previously described for the coupling of 
recombinant proteins with a His6 tag to preformed iscom matrix, i.e. iscom 
particles without any antigen (Andersson et al., 2001). Briefly, the iscom matrix 
consisting of Quil A, cholesterol, phosphatidyl choline and the chelating lipid 
IDA-TRIG-DSGE was loaded with Ni2+ by incubation in 0.1M NiCl2. Unbound 
Ni2+ was removed by passage through a PD-10 column, and the fractions 
containing matrix were identified by measuring the absorbance at 214 nm (the 
wavelength for Quil A). After that, the matrix (corresponding to approximately 2.3 
mg Quil A) was mixed with 319 µg rSAG1, incubated overnight at 4 °C and 
dialysed against phosphate-buffered saline (PBS). To examine whether the protein 
had bound to the matrix, an aliquot of the preparation was added to the top of a 
10-50% sucrose gradient and centrifuged at 200,000 × g and 10 °C for 17 hours. 
The gradient was divided into 16 fractions, which were tested for Quil A content 
by spectrophotometry (214 nm) and protein content by the Bradford test 
(Bradford, 1976). The fractions were also analysed by enzyme-linked 
immunosorbent assay (ELISA) to detect rSAG1 (Andersson et al., 2001). 
Microtitre plates were coated with serial dilutions of each fraction, and serum 
from mice chronically infected with T. gondii was used as a primary antibody. The 
morphology of rSAG1 iscoms was examined by electron microscopy, and the 
protein concentration was determined by the Bradford test. The rSAG1 iscoms 
were stored at –70 °C until used for the immunisation of mice. 
 
2.3 Animals and immunisations 
Female, 18-20 g, BABL/c and NMRI mice were obtained from the National 
Veterinary Institute, Sweden. All mice were kept in conventional cages. 
 
The mice were immunised subcutaneously (s.c.) at the base of the tail with 0.1 
ml of PBS containing rSAG1 iscoms, corresponding to a dose of 1.3 µg of protein 
and 10 µg of Quil A. Control mice were injected similarly with iscom matrix 
containing 10 µg of Quil A per dose, or with PBS. Booster immunisations were 
done once or twice with a 4-week interval.  
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2.4 Parasites 
Tachyzoites of the T. gondii RH strain were kept in continuous in vitro culture in 
Vero cells and used for preparation of T. gondii iscoms (Lundén, 1995), which 
were used as antigens in the ELISA and Western blot. The RH tachyzoites were 
also used for preparation of T. gondii lysate, which was used in the lymphocyte 
stimulation test. Challenge infections were performed with RH strain tachyzoites, 
and with tissue cysts of the Tg-SweF1 strain (Gustafsson et al., 1997) maintained 
in mice by passage every sixth month. 
 
 
2.5 Experimental design 
2.5.1 Determination of the challenge dose for the RH strain  
Twelve female NMRI mice were divided into three groups, with four mice in 
each. The mice were inoculated s.c. with 104, 105 or 106 tachyzoites of the RH 
strain. Clinical signs were observed twice daily, and when possible severely 
affected mice were killed instead of letting them die. 
 
2.5.2 Humoral and cellular immune responses 
Twenty BALB/c mice were divided into four groups, with five mice in each. 
Three of the groups were injected twice with either rSAG1 iscoms, iscom matrix, 
or PBS. The fourth group was inoculated intraperitoneally with 30 tissue cysts of 
the Tg-SweF1 strain, and served as an infected control group. Two weeks after the 
second immunisation, blood samples were collected, and the mice were killed and 
their spleens removed. The antibody responses were analysed by ELISA, and 
spleen cells were processed for analysis of cellular immune responses with the 
lymphocyte stimulation test (LST).  
 
2.5.3 Challenge infection with a virulent T. gondii strain 
Thirty-two BALB/c mice were divided into four groups, with eight mice in each. 
Group 1 was injected with rSAG1 iscoms and group 2 with iscom matrix. Groups 
3 and 4 were injected with PBS, and served as non-immunised challenged group 
and non-immunised non-challenged group, respectively. Booster immunisations 
were given after four and eight weeks. Sera were collected three weeks after the 
first immunisation and two weeks after each booster. Two weeks after the third 
immunisation, groups 1, 2 and 3 were inoculated s.c. with 104 RH strain 
tachyzoites and group 4 with 0.1 ml cell culture medium. All mice were weighed 
daily from two days before the challenge infection until the end of the experiment. 
Clinical signs were monitored and mortality recorded twice daily. However, when 
possible, severely affected mice were killed to avoid unnecessary suffering.  
 
2.5.4 Challenge infection with an avirulent T. gondii strain 
Thirty NMRI mice were divided into three groups, with ten mice in each. Group 1 
received rSAG1 iscoms, group 2 iscom matrix and group 3 PBS. Booster 
immunisations were given after four and eight weeks. Sera were collected three 
weeks after the first immunisation and two weeks after each booster. Two weeks 
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after the third immunisation, all mice were inoculated orally with 30 tissue cysts of 
the Tg-SweF1 strain. Thirty days after the challenge, the mice were killed and 
their brains examined, and the number of tissue cysts per brain was calculated. 
 
2.6 ELISA 
Antibody responses were analysed by ELISA as previously described (Andersson 
et al., 2001). To examine whether the antibodies induced by the rSAG1 would 
react with the native protein, iscoms containing tachyzoite surface antigens 
including SAG1 (Lundén, 1995) were used as coating antigen. The plates were 
coated with T. gondii iscoms or rSAG1 at a concentration of 1 µg/ml. Five percent 
non-fat dry milk in PBS was used as blocking agent. Individual mouse sera were 
tested in 3-fold serial dilutions starting at 1:30. Pooled sera from mice chronically 
infected with the Tg-SweF1 strain of T. gondii was used as the positive control 
serum and pooled sera from normal mice as the negative control. A rabbit anti-
mouse immunoglobulin (Ig) labeled with horseradish peroxidase (HRP) was used 
as secondary antibody at a dilution of 1:2000. All sera and the conjugate were 
diluted in PBS-Tween with 2% non-fat dry milk. The substrate was 1 mM 
tetramethylbenzidine in potassium citrate and the absorbance was read at 450 nm. 
Titres were calculated from interpolation of the linear part of the titration curves, 
and were expressed as the reciprocal of the serum dilution giving an optical 
density of 1.0. 
 
2.7 Immunoblotting 
SDS-PAGE and immunoblot analysis were performed to confirm the presence of 
rSAG1 protein in the iscom preparation, and to examine the antibody responses in 
vaccinated mice. T. gondii iscoms were used as antigen to investigate if the 
antibodies induced by the rSAG1 iscoms recognised SAG1 of parasite origin. The 
rSAG1 iscoms (0.6 µg protein per lane) and T. gondii iscoms (1.5 µg protein per 
lane) were separated under non-reducing conditions on a 12% separating gel. 
After the antigens were transferred to nitrocellulose membrane (45 µm pore size, 
Trans-Blot® Transfer Medium, Bio-Rad Laboratories, USA), the membranes were 
blocked with 5% non-fat dry milk in Tris-buffered saline (TBS). After being 
washed with TBS-Tween three times, the nitrocellulose membranes were 
incubated overnight with either pooled sera from mice immunised with rSAG1 
iscom, the positive control serum, the negative control serum or the monoclonal 
antibody (mAb) S13 (Harning et al., 1996), which were used as a marker for 
SAG1. The sera were diluted 1:100 in TBS-Tween with 2% non-fat dry milk. An 
HRP-conjugated rabbit anti-mouse Ig diluted 1:1000 in TBS-Tween with 2% non-
fat dry milk was used as secondary antibody and 3,3’-diaminobenzidine 
tetrahydrochloride (Sigma) as substrate. 
 
2.8 Lymphocyte stimulation test 
Cell-mediated immune responses were analysed by LST. Spleen cells were 
suspended in RPMI 1640 supplemented with 2 mM L-glutamine, 5×105 mM 2- 
mercaptoethanol, 50 IU/ml penicillin, 50 µg/ml streptomycin and 10% fetal calf 
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serum. The cells were dispensed into flat-bottomed 96-well culture plates 
(Corning Incorporated, Corning, NY, USA) with 2.5×105 cells in 100 µl per well, 
together with 100 µl medium containing T. gondii lysate (2, 6 and 18 µg/ml), 
rSAG1 (0.28, 0.83 and 2.5 µg/ml) or concanavalin A (Con A; 10 mg/ml). Control 
cultures without antigen or mitogen were included, and each kind of culture was 
set up in triplicate. After incubation for 96 hr in 5% CO2 at 37 °C, 0.5 mCi tritium-
labeled thymidine was added to each well. After another 18 hr incubation, the 
radioacitivity was measured as counts per minute (cpm), and the proliferative 
response was expressed as a stimulation index (SI) according to the formula: SI = 
mean cpm in stimulated cultures/mean cpm in control cultures.  
 
2.9 Enumeration of T. gondii cysts in mouse brains 
Each mouse brain was homogenised with a mortar and pestle in 1 ml PBS. From 
the homogenates, five 10 µl samples were each placed under a 12×12 mm cover 
slip and examined in a light microscope. The number of tissue cysts in the samples 
was counted and the number of tissue cysts per brain calculated. 
 
2.10 Statistical analysis 
One-way analysis of variance (ANOVA) was used to compare the survival times 
after virulent challenge. ANOVA and Tukey’s pairwise comparison were used for 
statistic comparison of the number of cysts per brain in the different groups. p < 
0.05 was considered statistically significant. 
 
3. Results 
3.1 Characterisation of rSAG1 iscoms 
The results of the analytical sucrose density gradient centrifugation are shown in 
Fig. 1A-C. According to the Bradford analysis and ELISA, the rSAG1 was 
recovered in fractions 2 and 7 from the bottom of the gradient. Also, the 
absorbance at 214 nm peaked in fractions 2 and 7, indicating the presence of Quil 
A in these fractions. Electron microscopy of the rSAG1 iscom preparation 
revealed the typical cage-like structures (Fig. 2). 
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Fig.1. The rSAG1 iscom preparation was analysed by density gradient centrifugation. Each 
fraction was read by spectrophotometer for Quil A content (A), and analysed with Bradford 
test for protein content (B) and ELISA for the presence of rSAG1 (C). 
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Fig. 2. Electron micrograph of rSAG1 iscoms (Photo: T. Nikkilä). 
 
3.2 Challenge dose of the RH strain 
Eight days post-infection, two of four mice given 104 tachyzoites died, and the 
other two died on day 9. The mice inoculated with 105 and 106 tachyzoites started 
to die on days 5 and 6, respectively, and all were dead on days 9 and 7 (Fig. 3). 
For the challenge experiments, the dose 104 was chosen since it was enough to 
cause lethal infection. 
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Fig.3.  Percentage survival of mice inoculated s.c. with 104 (○), 105 (×) or 106 (□) 
tachyzoites of the RH strain (n = 4). 
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3.3 Immune responses induced by rSAG1 iscoms 
The cellular immune responses were analysed by LST and an SI above 2.5 was 
considered to indicate significant stimulation (Kristensen et al., 1982). Cells from 
three of four mice immunised with rSAG1 iscoms (group 1) proliferated 
significantly when stimulated in vitro with rSAG1. However, when stimulated 
with T. gondii lysate significant proliferation was induced only in cells from one 
of five mice. rSAG1 stimulated cells from 4 of 5 chronically infected mice (group 
4) to proliferate but at a relative low level, while T. gondii lysate induced strong 
proliferative responses from this group. The level of proliferation was dose 
dependent and increased with the concentration of antigen (data not shown). Cells 
from mice given either iscom matrix or PBS (group 2 and 3) were not activated by 
rSAG1 or T. gondii lysate. 
 
Mice immunised with rSAG1 iscoms produced high antibody levels against 
rSAG1 but low levels against T. gondii iscoms. In contrast, mice chronically 
infected with T. gondii developed high antibody titres against T. gondii iscoms but 
only low antibody titres against rSAG1. Neither group 2 nor 3 produced 
measurable antibody responses against any of the antigen preparation (Table 1). 
 
Table 1. Proliferative responses and antibody titres in mice immunised with rSAG1 iscoms 
or infected with T. gondii 
 
  Stimulation Index (SI) Antibody titres against 
Group No. rSAG1 
2.5 μg/ml 
T. gondii lysate 
18 μg/ml 
Con A 
10 μg/ml
rSAG1 Tg iscoms 
  
1. rSAG1  1 19.6 2.2 15.0 >65610 636 
iscoms 2 20.0 1.3 308.6 >65610 267 
 3 1.7 0.6 64.5 >65610 140 
 4 NT 0.8 NT >65610 119 
 5 52.6 4.0 66.4 >65610 44 
  
2. iscom  1 2.2 1.2 208.0 <30 <30 
matrix 2 0.5 0.6 339.6 <30 <30 
 3 0.8 0.4 113.2 <30 <30 
 4 2.1 0.4 54.1 <30 <30 
  
3. PBS 1 0.9 0.7 43.5 <30 <30 
 2 0.8 0.7 46.5 <30 <30 
 3 0.7 0.8 86.8 <30 <30 
 4 1.2 1.5 58.6 <30 <30 
 5 1.3 1.2 14.7 <30 <30 
  
4. T. gondii  1 3.6 27.3 50.1 289 22529 
tissue cysts 2 3.8 14.6 103.7 66 33872 
 3 2.8 30.0 21.1 <30 39348 
 4 5.2 69.2 74.4 54 40980 
 5 1.7 14.2 26.1 226 31397 
  
Positive serum     258 >65610 
Negative serum     43 <30 
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3.4 Immunoblotting 
Sera collected from mice immunised with rSAG1 iscoms reacted with an antigen 
with an approximate molecular weight of 30 kDa in both rSAG1 iscoms and T. 
gondii iscoms. The mAb S13 against SAG1, which was used to confirm the 
presence of rSAG1 in the rSAG1 iscoms and to identify SAG1 in the T. gondii 
iscoms, gave a similar pattern to sera from the immunised mice. The positive 
serum recognised a large number of antigens in the T. gondii iscoms, while only a 
single band of approximately 30 kDa in the rSAG1 iscoms was stained. The 
rSAG1 iscoms did not react with the negative serum, while a pale band in the T. 
gondii iscoms was stained (Fig. 4). 
 
         A.            B. 
 
       C.            D. 
 
 
Fig. 4. Immunoblot with sera from mice immunised with rSAG1 iscoms (A), the 
monoclonal antibody S13 against SAG1 (B), positive serum from T. gondii infected mice 
(C) and negative serum from normal mice (D). Molecular weights (kDa) are indicated to the 
right. 
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3.5 Challenge infection with the virulent T. gondii strain 
Since it was found in the previous experiment that two immunisations with rSAG1 
iscoms only induced relatively low antibody titres against T. gondii antigen, the 
mice were immunised three times before challenge infection. However, despite 
increased antibody titres (Table 2), mice immunised with rSAG1 iscoms were not 
protected against the virulent challenge, and appeared to be as susceptible as both 
the non-vaccinated control and the iscom matrix group. All the infected groups 
started to lose weights from day 5 post-infection while the weights of the 
uninfected group remained at the same level as before inoculation. Moreover, all 
infected mice died within nine days after the challenge and, although the mean 
survival time for the immunised mice was slightly longer, this difference was not 
significant (p = 0.179; Table 3). 
 
Table 2. Antibody titres of BALB/c mice immunised three times with rSAG1 iscoms before 
challenge infection with RH strain tachyzoites 
 
Antibody titres a against 
rSAG1 T. gondii iscoms 
After 1st immunisation 216 (<30-591) <30 
After 2nd immunisation >65610 481(65-3447) 
After 3rd immunisation >65610 1743(216-7107) 
Positive serum b 226 >65610 
Negative serum <30 <30 
 
 a  Geometric mean and range, n = 8 
 b  From mice chronically infected with T. gondii Tg SweF1 strain 
 
Table 3. Survival times of BALB/c mice challenged with RH strain tachyzoites 
 
Group (n = 8) Mean survival times (Days ± SD) 
1. rSAG1 iscoms 8.13 ± 0.64
2. Iscom matrix 7.88 ± 0.35
3. PBS 7.63 ± 0.52
 
 
3.6 Challenge with the cyst-forming strain 
The aim of this experiment was to evaluate whether immunisation with the rSAG1 
iscom could decrease the cyst burden after challenge with the cyst-forming strain 
Tg SweF1. Antibody responses were analysed after each immunisation, and high 
antibody titre against both rSAG1 and T. gondii iscoms were demonstrated after 
the last immunisation (Table 4). Thirty days after infection, significantly lower 
numbers of brain cysts were found in mice immunised with rSAG1 iscoms than in 
mice given PBS (p < 0.05; Fig. 5). However, the number of brain cysts found in 
mice given iscom matrix was not significantly different from those found in the 
immunised group or in the PBS control group. 
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Table 4. Antibody titres of NMRI mice immunised three times with rSAG1 iscoms before 
challenge infection with Tg SweF1 strain 
 
 Antibody titres a against
 rSAG1 T. gondii iscoms
After 1st immunisation <30 <30
After 2nd immunisation 3192 (526-80815) (<90-546)
After 3rd immunisation 288100 (143678-427318) 2901(373-9205)
Positive serum b 206 >65610
Negative serum <30 <30
 
 a  Geometric mean and range, n = 8 
 b  From mice chronically infected with T. gondii Tg SweF1 strain 
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Fig. 5. Average number of tissue cyst in the brain of NMRI mice thirty days after the 
challenge infection. The mice were immunised with rSAG1 iscoms, injected with iscom 
matrix or PBS (n = 10). * = significantly different, p < 0.05. 
 
4. Discussion 
The immunogenicity of iscoms is dependent on the physical binding of the 
antigens to the iscom particle (Lövgren-Bengtsson, 1998). Analytical density 
gradient centrifugation is often used to examine iscom preparations. In a 10-50% 
sucrose gradient, iscoms and iscom matrix are typically found just below the 
middle of the gradient (Andersson et al., 2001; Lövgren and Morein, 1988). In the 
present study, a large proportion of the rSAG1 appeared at this level, but a 
substantial amount was also detected just above the bottom of the gradient where 
protein aggregates are often found. According to the absorbance at 214 nm, Quil 
A was also present at these two levels, indicating that the protein had bound 
efficiently to the iscom matrix. However, the apparent presence of Quil A near the 
bottom of the gradient is difficult to explain. Since the spectrophotmetric method 
used is not entirely specific for QuilA, other substances such as precipitated 
proteins can cause an unspecific increase in absorbance. Nevertheless, it can be 
*
 *
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concluded that a considerable proportion of the rSAG1 had bound to the iscom 
matrix. 
 
In the initial immunisation experiment it was found that the rSAG1 iscoms 
efficiently induced both humoral and cellular immune responses against rSAG1. 
However, when T. gondii antigen was used as antigen in the ELISA only low 
levels of antibodies were detected. Similarly, a T. gondii specific poliferative 
response could only be detected in one of five immunised mice. It is well known 
that many of the B-cell epitopes of SAG1 are conformational, and several efforts 
to express the protein in bacteria have failed because of incorrect folding (Burg et 
al., 1988). The recombinant protein used in the present study has previously been 
shown to be properly folded (Harning et al., 1996). To examine if the 
conformation could have been affected by coupling to the iscom matrix, the 
iscoms were analysed by immunblotting. Since the monoclonal antibody S13, 
which is directed to a conformational epitope of the native SAG1 (Harning et al., 
1996), recognised the protein in the iscom preparation, incorrect folding is 
probably not the reason for the low responses to the native antigen.  
 
Because of the poor immune responses against T. gondii antigen recorded in the 
initial study, an additional third immunisation dose was given before the challenge 
infection. This resulted in substantially increased antibody titres against the 
parasite antigen. However, this was not sufficient to protect the mice against 
challenge infection with the RH strain. 
 
Before the challenge experiment, three doses of RH tachyzoites were tested. 
Subsequently, the lowest of dose, 104 tachyzoites, was selected since it was 
enough to cause a lethal infection. This can be compared to the doses used in other 
experiments, for example 2.5×104 (Lindsay et al., 1990) in Swiss Webster mice, 
105 (Petersen et al., 1998) in NMRI mice and 105 tachyzoites in C3H and BALB/c 
mice (Nielsen et al., 1999). 
 
In the next challenge experiment, when a less virulent strain was used, it was 
found that mice immunised with rSAG1 iscoms had significantly less brain cysts 
than the control group given PBS only. This indicated that some degree of 
protective immunity against T. gondii infection was induced by the rSAG1 iscom. 
 
Infection with T. gondii induces both antibody and cell-mediated immune 
responses. Since the protozoan is an intracellular parasite, the cellular immune 
mechanisms are the main defense of the host. The results from numerous reports 
illustrate that cellular immunity is more important against T. gondii infection than 
the antibody response. Passive transfer of T cells, particularly the CD8+ subset, 
from chronically infected animals can protect naïve recipients against challenge 
with a virulent strain (Parker et al., 1991; Suzuki and Remington, 1988). CD8+ T 
cells from immune mice are cytotoxic to T. gondii infected cells (Hakim et al., 
1991), and interferon gamma (IFN-γ), produced by CD4+, CD8+ T cells or natural 
killer (NK) cells, is considered to be important mediator of resistance against T. 
gondii infection (Suzuki et al., 1988). Neutralisation of this cytokine results in 
increased susceptibility to the parasite (Suzuki and Remington, 1990). The 
protective activity of CD8+ T cells is dependent on IFN-γ (Suzuki and Remington, 
1990). Although the CD8+ T cells are crucial for protection against T. gondii, 
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CD4+ T cells are also important, and regulate immunity through secretion of IFN-γ 
and other cytokines (Gazzinelli et al., 1991).  
 
In the current study, the failure of rSAG1 iscoms to protect mice against 
challenge with the virulent strain could be due to poor stimulation of cellular 
immunity. After two immunisations, T. gondii specific proliferation could only be 
detected in one of five mice. However, the cellular response was only examined 
after the second immunisation, and further experiments are needed to investigate 
the effects of the last booster immunisation.  
 
Several studies have been published of the immune responses and protective 
effect induced by immunisation with various immunogens derived from SAG1. 
For instance, mice given a SAG1 derived peptide developed low antibody titres, 
and partial protection against infection, which was demonstrated as 35% reduction 
in brain cyst burden (Velge-Roussel et al., 1997). Reduction of the brain cyst load 
was also reported in mice immunised with rSAG1 plus interleukin-12 (IL-12), a 
mediator of Th1 responses (Letscher-Bru et al., 1998). Immunisation with rSAG1, 
expressed in E. coli and with alum as adjuvant, significantly protected mice from 
challenge infection with RH strain tachyzoites (Petersen et al., 1998). DNA 
vaccines based on the SAG1 gene have also been evaluated, and were in one study 
found to induce nearly complete protection against a lethal infection with the RH 
strain (Nielsen et al., 1999). In another study, both reduced mortality and fewer 
brain cysts were observed in the immunised mice (Couper et al., 2003).  
 
The protective effect recorded as reduction of brain cyst burden in the present 
study leads to the suggestion that further studies should be encouraged. The 
immunisation dose used in the present study was based on the recommended dose 
of Quil A that can be used without risk of negative effects (Lövgren-Bengtsson, 
1998). Each dose contained 1.3 µg protein, which was relatively low compared to 
that used by, for example, Petersen et al. (1998) who gave four doses of 10 µg of 
rSAG1. It is possible that the rSAG1 iscoms could be improved by coupling more 
protein to the matrix to increase the ratio of protein to Quil A, so that higher 
immunisation doses could be given.  
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General conclusions 
 
In general conclusion, although immunisation with rSAG1 iscoms did not 
protect mice from the lethal challenge infection, partial protection was induced as 
demonstrated by the reduction of brain cyst load after inoculation with an avirulent 
strain. 
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